Ceramide and S1P Agonist Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into neural or glial cells face challenges in controlling differentiation, leading to uncontrolled proliferation and the risk of teratoma formation, which limits their clinical use in treating neurodegenerative diseases due to the presence of residual pluripotent cells that can form inappropriate tissues.
Innovation Solution
A method involving culturing pluripotent stem cells with ceramide compounds and sphingosine-1-phosphate receptor agonists to enrich for oligodendrocyte precursor cells (ODPCs) that do not form teratomas, allowing for further differentiation into neural and glial cell types, thereby reducing the risk of teratoma formation and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pluripotent stem cells are used for treating neurodegenerative diseases, then therapeutic potential is improved, but risk of teratoma formation increases
Solution Approach 1:
The patent applies preliminary action by treating pluripotent stem cells with ceramide compounds and S1P receptor agonists before transplantation to induce differentiation into neural/glial cells. This pre-differentiation step eliminates residual pluripotent cells that could form teratomas, while preserving the therapeutic potential of the differentiated cells for treating neurodegenerative diseases.
Solution Approach 2:
The patent applies preliminary anti-action by using ceramide compounds and S1P receptor agonists to actively eliminate residual pluripotent cells before transplantation. This pre-treatment creates an anti-teratoma effect by inducing apoptosis or differentiation of any remaining pluripotent cells, counteracting the harmful potential before the cells are implanted.
2Manufacturing precision
If differentiation control is improved, then teratoma formation is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical environment of stem cell culture through the addition of ceramide compounds and S1P receptor agonists. These chemical parameters trigger specific signaling pathways that drive differentiation toward neural and glial lineages, providing precise control over cell fate without requiring complex physical or mechanical systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively eliminates teratoma-forming cells and promotes the differentiation of stem cells into specific neural and glial cell types, ensuring safe and effective transplantation for treating neurodegenerative diseases by reducing the risk of teratoma formation and enhancing tissue repair.
Implementation Method 1
The present invention provides a cell culture enriched for sphingolipid enhanced neural stem cells (SENSe), preferably sphingosine-responsive glial cells, and more preferably oligodendrocyte precursor cells (ODPCs). The ODPC enriched cell culture of the present invention does not form teratomas when transplanted in vivo.
Implementation Method 2
The present invention further provides a method of producing an ODPC enriched cell culture in vitro that does not form teratomas, and is capable of further differentiating into dendrocyte cell types. Such method comprises the steps of: a) contacting a pluripotent stem cell culture with a medium comprising a ceramide compound, and b) contacting the pluripotent stem cell culture with a medium comprising a sphingosine-1-phosphate (S1P) receptor agonist
Data Source
AI summary
The present invention provides a cell culture enriched for sphingolipid enhances neural stem cells (SENSe), particularly oligodendrocyte precursor cells (ODPCs), that do not form teratomas after transplanted in vivo. Methods for producing and use of the invention ODPCs or the cell culture enriched with these ODPCs for stem cell therapy are also provided. The invention method comprises culturing a stem cell culture with a cell culture medium comprising a ceramide compound and a S1P receptor agonist in sequence, overlapping intervals or concurrent manners. The present invention further provides a cellular or gene therapy using a composition comprising a ceramide compound in conjunction with a S1P1 agonist to proliferate or differentiate endogeneous neural stem cells to ODPCs and further to oligodendrocytes.